Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 1/20 | 0.58 |
| ▸ | ACE | P12821 | 5/20 | 0.57 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.57 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.51 |
| ▸ | F2 | P00734 | 2/20 | 0.51 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.51 |
| ▸ | DPP4 | P27487 | 1/20 | 0.48 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.48 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.48 |
| ▸ | CMA1 | P23946 | 1/20 | 0.48 |
| ▸ | PRCP | P42785 | 1/20 | 0.47 |
| ▸ | PREP | P48147 | 2/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13533689 | 1.00 | REN (0.58) | RENACEACE2CTRB1F2 | |
| SCHEMBL8265581 | 0.92 | REN (0.59) | RENACEACE2CTRB1F2 | |
| SCHEMBL8265650 | 0.92 | REN (0.59) | RENACEACE2CTRB1F2 | |
| SCHEMBL13533688 | 0.89 | REN (0.55) | RENACEACE2CTRB1F2 | |
| SCHEMBL13533687 | 0.87 | PRCP (0.63) | RENACEACE2CTRB1F2 | |
| SCHEMBL8252248 | 0.85 | REN (0.56) | RENACEACE2CTRB1F2 | |
| SCHEMBL7319431 | 0.85 | REN (0.65) | RENACEACE2CTRB1F2 | |
| SCHEMBL14117862 | 0.85 | REN (0.55) | RENACEACE2CTRB1F2 | |
| SCHEMBL5970431 | 0.83 | ACE (0.76) | RENACEACE2 | |
| SCHEMBL8268894 | 0.83 | ACE (0.76) | RENACEACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022646-A1 | METHOD OF NEUTRALISING ORGANOBORONATES WITH ACIDS | TRIGEN LIMITED (GB) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022646-A1 | METHOD OF NEUTRALISING ORGANOBORONATES WITH ACIDS | LIPC, CYP8B1, SCD | REN 2004/4885ACE 1581/4885ACE2 2518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.